# Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine

> **NCT00920517** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 25 (actual)

## Conditions studied

- Dengue Fever

## Interventions

- **BIOLOGICAL:** rDEN2/4delta30(ME) vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00920517
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920517, "Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00920517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*